Prostaglandin analogue use has grown at the expense of beta-blockers and trabeculectomy in Scotland

Article

The increasing use of prostaglandin analogues in Scotland has led to an increase in prescribing rates and a rapid increase in cost, whilst prescribing of beta-blockers has declined and trabeculectomy rates have fallen, according to a study published in the February 2008 issue of Eye.

The increasing use of prostaglandin analogues in Scotland has led to an increase in prescribing rates and a rapid increase in cost, whilst prescribing of beta-blockers has declined and trabeculectomy rates have fallen, according to a study published in the February 2008 issue of Eye.

Dr Shona Macleod of Aberdeen Royal Infirmary and University of Aberdeen, Scotland and team evaluated the changing trends in glaucoma management in Scotland between 1994 and 2004 by conducting a retrospective analysis of national health statistics. The outcome measures were trabeculectomy rates, corrected for population likely to be at risk of glaucoma (PLG), prescribing volume and cost for glaucoma medications.

Between 1994 and 2004, PLG (calculated from estimates of prevalence in individuals aged 40 years and older, based on published epidemiological studies) increased by 16.6%. During the same time period, trabeculectomy rates fell from 46 per 1000 PLG in 1994 to 15.4 per 1000 PLG in 2004, a decrease of 67%. The cost of prescribing increased by 122% compared with an increase in number of items per 1000 PLG by 27.5%.

In 1994, beta-blockers accounted for 65.2% of prescribed drugs; by 2004, this had dropped to 33%. Since their introduction, the prescribing of prostaglandin analogues has increased rapidly and in 2004, they accounted for 39.4% of prescribed drugs.

Thus the rapidly rising cost of prostaglandin analogues has not impacted negatively on their use, which had in fact, by 2004 in Scotland, overtaken the prescribing of the more traditional beta-blockers and trabeculectomies.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.